CytRx Corp., of Los Angeles, said it completed enrollment of 140 patients in its Phase IIb study testing oral retinoid compound tamibarotene in combination with chemotherapeutic agents as a first-line treatment in advanced non-small-cell lung cancer

NovaBay Pharmaceuticals Inc., of Emeryville, Calif., said partner Galderma SA, of Lausanne, Switzerland, started the South African arm of its Phase IIb study testing a topical formulation of NVC-422 for the treatment of impetigo

Data from a Phase IIb trial evaluating the safety and efficacy of tuberculosis (TB) vaccine MVA85A showed that a single dose of the vaccine was not sufficient to confer statistically significant protection against TB or infection in infants vaccinated at birth with the Bacille Calmette-Guérin (BCG) vaccine...MVA85A also is being investigated in a Phase IIb study in HIV-positive individuals in Senegal and South Africa, a Phase IIa study in infants born to HIV-positive mothers in South Africa and

CytRx Corp., of Los Angeles, said a data safety monitoring committee recommended continuing a Phase IIb trial of tamibarotene with chemotherapy in non-small-cell lung cancer...Vanda Pharmaceuticals Inc., of Washington, said top-line data from its Phase IIb/III study, dubbed MAGELLAN, testing tasimelteon as a monotherapy in major depressive disorder (MDD) did not meet the primary endpoint of change from baseline in the Hamilton Depression Scale after eight weeks of treatment compared to placebo

signed a nonbinding letter of intent to collaborate on the initial Phase IIb portion of the trial

Molecular Partners licensed rights to MP0112 to Allergan Inc., of Irvine, Calif., which is testing the drug in a Phase IIb trial in exudative age-related macular degeneration. (See BioWorld Today, May 11, 2011

Cytos Biotechnology Ltd., of Zurich, Switzerland, said a technical issue was identified with the rubber stoppers used to close the injection vials containing clinical trial material for its Phase IIb study testing lead candidate CYT003 in allergic asthma

CoDa Therapeutics Inc., of San Diego, reported Phase IIb data showing that Nexagon in patients with chronic venous leg ulcers was found to be safe and produced an increase in complete healing in the vehicle-controlled trial

Edison Pharmaceuticals Inc., of Mountain View, Calif., said it started a Phase IIb study testing EPI-743 in patients with Friedreich's ataxia

NovaBay Pharmaceuticals Inc., of Emeryville, Calif., said the first patients have been enrolled in India into its global Phase IIb BAYnovation clinical study, investigating NVC-422 ophthalmic solution as a treatment of adenoviral conjunctivitis, a highly contagious form of "pink eye" for which there is an unmet ocular medical need

Synergy Pharmaceuticals Inc., of New York, said plecanatide, its oral guanylate cyclase C agonist for chronic idiopathic constipation, was well tolerated and met the primary and key secondary endpoints in a Phase IIb/III study

Synergy Pharmaceuticals Inc., of New York, said dosing has commenced in a Phase IIb trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome (IBS-C

Neurocrine Biosciences Inc., of San Diego, said it started a Phase IIb trial (Kinect 2 Study) of its vesicular monoamine transporter 2 compound, NBI-98854...ViroPharma Inc., of Exton, Pa., and Halozyme Therapeutics Inc., of San Diego, said ViroPharma started a Phase IIb dose-ranging study to test subcutaneous administration of Cinryze (C1 esterase inhibitor [human]) in combination with Halozyme's Enhanze technology, which uses recombinant human hyaluronidase enzyme

Pharmalink AB, of Stockholm, Sweden, began a Phase IIb trial of Nefecon (Nefigan) for IgA nephropathy

Celladon Corp., of San Diego, dosed its first patient in Europe in a Phase IIb trial of Mydicar for heart failure

Biotie Therapies Corp., of Turku, Finland, reported top-line data from a Phase IIb study showing that tozadenant (SYN115), its adenosine A2a antagonist, met the primary endpoint of decreasing the "off" time in Parkinson's patients experiencing levodopa-related end-of-dose wearing off vs

Sarepta Therapeutics Inc., of Cambridge, Mass., said updated data from Study 202, its open-label, Phase IIb extension study of eteplirsen for the treatment of Duchenne's muscular dystrophy, showed that patients treated with eteplirsen for 62 weeks and evaluable on ambulatory measures (modified intent-to-treat population) maintained a statistically significant clinical benefit on the primary clinical outcome measure, the six-minute walk test, compared to patients who received placebo for 24 weeks

Cytokinetics Inc., of South San Francisco, opened enrollment of the third and final cohort in its ATOMIC-AHF Phase IIb trial of omecamtiv mecarbil in left ventricular systolic dysfunction in patients hospitalized for heart failure

Anthera Pharmaceuticals Inc., of Hayward, Calif., reported additional data from its Phase IIb PEARL-SC study at the Asian Lupus Summit meeting in Manila, Philippines, related to the effect of blisibimod on renal disease in lupus